Actavia Life Sciences, Inc.
RASP · OTC
9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.11 | 0.06 | 0.06 | -0.00 |
| FCF Yield | -0.07% | -37.33% | -7.10% | -4.86% |
| EV / EBITDA | -30.78 | 4.00 | -19.09 | -10.23 |
| Quality | ||||
| ROIC | 242.87% | -9.60% | 11.98% | 252.04% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.00 | 0.46 | 0.37 | 0.05 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 97.28% | -6.57% | -16.74% | -171.34% |
| Safety | ||||
| Net Debt / EBITDA | -0.36 | 0.71 | -2.35 | -0.91 |
| Interest Coverage | -19.90 | 0.15 | -0.48 | -131.02 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -0.01 | -2.19 |
| Cash Conversion Cycle | 0.00 | 0.00 | -1,085,437.93 | -212,726.69 |